Japan Pharmaceuticals Market 2024-2030
  • CHOOSE LICENCE TYPE
Consulting Services
    How will you benefit from our consulting services ?

Japan Pharmaceuticals Market 2024-2030

Last Updated:  Apr 25, 2025 | Study Period: 2024-2030

JAPAN PHARMACEUTICALS MARKET 

 

INTRODUCTION

The Japanese pharmaceutical industry has experienced modest growth rates in recent years. It has been challenging for pharmaceutical companies to launch new, innovative drugs due to a complicated regulatory and pricing process, as well as ongoing price reductions.

infographic: Japan Pharmaceuticals Market, Japan Pharmaceuticals Market Size, Japan Pharmaceuticals Market Trends, Japan Pharmaceuticals Market Forecast, Japan Pharmaceuticals Market Risks, Japan Pharmaceuticals Market Report, Japan Pharmaceuticals Market Share

The government decision to promote generic medications in an effort to lower healthcare costs in Japan is another factor contributing to the market's stagnation.

 

Generics volume share has increased by more than a factor of two during the past ten years and is still growing.

 

In addition to the booming generic medication market, the planned change of the Japanese pharmaceutical industry will be fueled by a rise in the usage of biosimilars, which are predicted to have the quickest future growth rate due to the wide range of medicines now in development.

 

Japanese corporations are being forced to adjust to a shifting market climate as several medicine patents have started to expire.

 

With a proportion in the global market, the Japanese pharmaceutical industry is still among the largest.The Japanese market is changing, but it also presents a number of opportunities and room for expansion.

 

JAPAN PHARMACEUTICALS MARKETSIZE AND FORECAST

 

The Japan pharmaceuticals market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

 

JAPAN PHARMACEUTICALS MARKETCOVID-19 IMPACT

When the SARS-CoV-2 virus caused the coronavirus disease (COVID-19) to spread, pharmaceutical companies all over the world tried to produce medicines to treat or cure the illness.

 

According to the extra budget plans after the outbreak, the Japanese government mostly sponsored overseas partnerships instead of domestically creating the vaccine.

 

Nevertheless, five domestically produced vaccinations are presently undergoing testing. The first COVID-19 vaccine, the mRNA vaccine, was licensed by the Japanese government.

 

Then, vaccinations started for medical personnel mostly for adults. The viral vector vaccine and mRNA vaccine from AstraZeneca were authorised.

 

Following clearance, the Moderna vaccine was administered in conjunction with Takeda Pharmaceutical Company Limited, the regional distributor.

 

Due to adverse effects experienced by older individuals that were reported internationally, AstraZeneca's vaccine was only initially distributed to the elderly.

 

The government switched over to the recombinant protein-based vaccination Novavax in place of AstraZeneca's, with Takeda serving as the regional producer and distributor. 

JAPAN PHARMACEUTICALS MARKETCOMPANY PROFILE

 

JAPAN PHARMACEUTICALS MARKETTHIS REPORT WILL ANSWER FOLLOWING QUESTIONS

  1. What is the average cost per Japan pharmaceuticals market right now and how will it change in the next 5-6 years?
  2. Average cost to set up a pharmaceuticals market in Japan?
  3. How many Japan pharmaceuticals are manufactured per annum globally? Who are the sub-component suppliers in different regions?
  4. What is happening in the overall public, globally?
  5. Cost breakup of a Japan pharmaceuticals market and key vendor selection criteria
  6. Where is the Japan pharmaceuticals market manufactured? What is the average margin per equipment?
  7. Market share of Japan pharmaceuticals market manufacturers and their upcoming products
  8. The most important planned Japan pharmaceuticals market in next 2 years
  9. Details on network of major Japan pharmaceuticals market and pricing plans
  10. Cost advantage for OEMs who manufacture Japan pharmaceuticals market in-house
  11. 5 key predictions for next 5 years in Japan pharmaceuticals market
  12. Average B-2-B Japan pharmaceuticals market price in all segments
  13. Latest trends in Japan pharmaceuticals market, by every market segment
  14. The market size (both volume and value) of Japan pharmaceuticals market in 2024-2030 and every year in between?
  15. Global production breakup of Japan pharmaceuticals market, by suppliers and their OEM relationship

 

 

 

Sl noTopic
1Market Segmentation
2Scope of the report
3Abbreviations
4Research Methodology
5Executive Summary
6Introduction
7Insights from Industry stakeholders
8Cost breakdown of Product by sub-components and average profit margin
9Disruptive innovation in the Industry
10Technology trends in the Industry
11Consumer trends in the industry
12Recent Production Milestones
13Component Manufacturing in US, EU and China
14COVID-19 impact on overall market
15COVID-19 impact on Production of components
16COVID-19 impact on Point of sale
17Market Segmentation, Dynamics and Forecast by Geography, 2024-2030
18Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030
19Market Segmentation, Dynamics and Forecast by Application, 2024-2030
20Market Segmentation, Dynamics and Forecast by End use, 2024-2030
21Product installation rate by OEM, 2023
22Incline/Decline in Average B-2-B selling price in past 5 years
23Competition from substitute products
24Gross margin and average profitability of suppliers
25New product development in past 12 months
26M&A in past 12 months
27Growth strategy of leading players
28Market share of vendors, 2023
29Company Profiles
30Unmet needs and opportunity for new suppliers
31Conclusion
32Appendix